Lotronex REMS Update Now Allows E-Prescribing

Electronic prescriptions are now allowed for Lotronex
Electronic prescriptions are now allowed for Lotronex

The Food and Drug Administration (FDA) has modified the Risk Evaluation and Mitigation (REMS) for Lotronex (alosetron HCl; Sebela) indicated for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have not responded adequately to conventional therapy. 

Related Articles

Changes to the REMS program include:

    — Prescribers no longer need to affix prescribing program stickers to written prescriptions for Lotronex or Alosetron HCl

    — Pharmacies no longer need to only dispense Lotronex or Alosetron HCl for a paper prescription with an affixed prescribing program stickerv

    — Electronic prescriptions are now allowed 

    — Patients no longer need to complete and submit a Patient Acknowledgment Form; a Patient Education Sheet is now available for the prescriber to discuss with the patient

Lotronex is available as 0.5mg and 1mg strength tablets in 30-count bottles. 

For more information call (844) 732-3521 or visit LotronextREMS.com.